Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Jolt Health Announces New CEO and Director To Lead Biotechnology, Healthcare And AI Initiatives

Jolt Health, the Company, is thrilled to announce that Mr. Gerald Tritt has joined the Company as a Director and CEO. Mr. Tritt is a seasoned entrepreneur with a proven track record of success in the public markets and vast experience in various industries.

AiThority Interview Insights: AiThority Interview with Triveni Gandhi, PhD and Responsible AI Lead at Dataiku

As an early stage investor, Mr. Tritt has co-founded and co-owned several restaurant concepts, including the  one of Canada’s most prominent fast food chains, where he served as CEO. He has also consulted with international biotech companies in the health and wellness sector on their logistics and organizational structure, leveraging his extensive knowledge of e-commerce and online presence development to expand their reach during the covid-19 pandemic.

Mr. Tritt has held senior management positions in both national and international hospitality groups, providing him with valuable leadership and operations skills that will prove essential in his role as CEO of Jolt Health. As an investor in multiple startups across different industries, he brings firsthand capital markets experience, an extensive network, corporate governance and strong private equity background to the company.

“We are delighted to welcome Mr. Tritt to the Jolt Health team as our new CEO and Director,” Said Zachary Stadnyk, the Company’s outgoing CEO. “His diverse background in various industries, exceptional leadership skills, and his vast experience in the public markets make him the perfect candidate to lead Jolt Health’s new vision in Healthcare, Biotechnology and AI. We believe that his addition to the team will be instrumental in taking the company to new heights and we look forward to the future under his leadership.”

Mr. Tritt stated, “I am thrilled to join Jolt Health and lead the company’s ambitious initiatives. I believe that the combination of Jolts’s existing expertise and resources, together with my experience and network, will enable us to develop innovative solutions and exciting i********* opportunities. I am motivated about the opportunity to create value for our shareholder and to help Jolt Health achieve its full potential.”

Related Posts
1 of 40,455

Read More about AiThority InterviewAiThority Interview with Arijit Sengupta, CEO and Founder at Aible

The appointment of Mr. Tritt as CEO and Director is effective immediately, and he will work closely with the Jolt Health team to develop and execute the Company’s strategic plan.

On behalf of the board of directors and management, the Company’s wishes to thank Mr. Stadnyk for his instrumental role in publicly listing, financing and growing the company thus far. He will remain a close advisor to the company on corporate finance and acquisition related matters going forward.

Zachary Stadnyk, CEO and Director

Jolt Health is a leading healthcare, biotechnology and artificial intelligence company dedicated to revolutionizing global healthcare. The company currently holds exclusive licenses for innovative therapeutic and pharmaceutical products throughout Europe, the UK, and North America. The company is committed to transforming the industry through research, collaboration, and technological advancement, sharping the future of healthcare worldwide.

 Latest AiThority Interview Insights : AiThority Interview with Alex Mans, Founder and CEO at FLYR Lab

 [To share your insights with us, please write to] 

Comments are closed.